Skip to main content

Day: May 18, 2023

Whitestone REIT Elects New Board Member, Julia Buthman

Whitestone REIT’s Board: Julia Buthman, Jeff Jones, Amy Feng, David Taylor, Nandita Berry and David Holeman Whitestone REIT’s Board: Julia Buthman, Jeff Jones, Amy Feng, David Taylor, Nandita Berry and David HolemanHOUSTON, May 18, 2023 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE:WSR) (“Whitestone” or the “Company”) announces the addition of Julia Buthman to the Company’s Board of Trustees, elected May 12th at Whitestone’s annual shareholder’s meeting. Julia is a seasoned investment professional with more than 35 years of investing in senior debt, subordinated debt and structured equity. She is a former Managing Director at Prudential Private Capital and has extensive experience on both non-profit and for-profit boards. “Julia’s election to the Whitestone board adds to the board’s already strong depth of experience,” stated Chairman...

Continue reading

FreightCar America, Inc. Announces Appointment of Nicholas J. Randall as Chief Operating Officer

Company adds to its executive leadership team as it continues to grow and focus on delivering superior manufacturing excellence and customer satisfaction CHICAGO, May 18, 2023 (GLOBE NEWSWIRE) — FreightCar America, Inc. (Nasdaq: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer of railroad freight cars, announced today the appointment of Nicholas J. Randall as the Company’s Chief Operating Officer (COO), effective June 26, 2023. Randall will report to James R. Meyer, President and Chief Executive Officer. “I am thrilled to welcome Nick to the FreightCar America team as our Chief Operating Officer. He is an accomplished business leader with deep and global experience in the heavy durable industrial and consumer industries. He brings a proven track record of growing companies by driving success through operational...

Continue reading

Orgenesis Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus Vectors

GERMANTOWN, Md. and PRAGUE, Czech Republic, May 18, 2023 (GLOBE NEWSWIRE) — (NASDAQ: ORGS) (“Orgenesis”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) through its US-based point-of-care (POCare) services subsidiary, Morgenesis LLC (“Morgenesis”), has signed a collaboration agreement with SCTbio, a full-service contract development and manufacturing organization (CDMO) specializing in cell-based therapy and viral vectors. The goal of the collaboration is to open new point-of-care (POCare) sites within the Czech Republic and leverage SCTbio’s GMP facility for the production of lentivirus vectors to support Morgenesis’ POCare worldwide customers, including use in CAR-T cell and gene therapies (CGTs). Orgenesis’ POCare Platform, including its Orgenesis Mobile Processing Units and Labs...

Continue reading

FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa Plan to file supplemental New Drug Application in ChinaSAN FRANCISCO and BEIJING, May 18, 2023 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) and its subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. today announced positive topline data from Company’s Phase 3 clinical study of roxadustat for treatment of anemia in patients receiving concurrent chemotherapy treatment for non-myeloid malignancies in China. Roxadustat (爱瑞卓®) demonstrated non-inferiority compared to recombinant erythropoietin alfa (SEPO®) on the primary endpoint of change in hemoglobin (Hb) level from baseline to the average level during weeks 9-13. In the preliminary safety analysis, the adverse event profile of roxadustat was generally consistent with previous findings...

Continue reading

Mullen Trades Above $1 Minimum Bid Price Requirement for 10 Consecutive Days

Mullen Automotive Trades on NASDAQ Capital Markets Stock Ticker Symbol: MULNBREA, Calif., May 18, 2023 (GLOBE NEWSWIRE) — via IBN — Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today that its stock has traded above Nasdaq’s $1 minimum bid price requirement for 10 consecutive days. On Sept. 7, 2022, Nasdaq provided notice to the Company that, based on the previous 30 consecutive business days, the Company’s listed common stock no longer met the minimum $1 bid price per share requirement as set forth in Nasdaq Listing Rule 5810(c)(3)(A)(ii) (the “Deficiency”). The Company was provided 180 calendar days, or until March 6, 2023, to regain compliance. On March 8, 2023, Nasdaq approved the Company’s request for a 180-day extension, through Sept....

Continue reading

Tremor International Ltd. to Announce First Quarter 2023 Financial Results on May 30, 2023

Conference call and webcast to be held May 30, 2023, at 9:00 AM ET and 2:00 PM BST NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) — Tremor International Ltd. (AIM/NASDAQ: TRMR), a global leader in data-driven video and Connected TV (“CTV”) advertising technology offering an end-to-end platform that enables advertisers to optimize their campaigns and media companies to maximize inventory yield, will release its financial results for the first quarter ended March 31, 2023 before the U.S. market opens on Tuesday, May 30, 2023. Tremor International will host a webcast and conference call with Ofer Druker, Chief Executive Officer, and Sagi Niri, Chief Financial Officer, at 6:00 AM PT, 9:00 AM ET, and 2:00 PM BST on the same date to discuss the Company’s financial results. Webcast and Conference Call DetailsTremor International First Quarter...

Continue reading

Regency Centers to Acquire Urstadt Biddle Properties in All-Stock Transaction

JACKSONVILLE, Fla. and GREENWICH, Conn., May 18, 2023 (GLOBE NEWSWIRE) — Regency Centers Corporation (“Regency”) (Nasdaq: REG) and Urstadt Biddle Properties Inc. (“Urstadt Biddle” or “UBP”) (NYSE: UBA and UBP) today announced that the two companies have entered into a definitive merger agreement (the “Agreement”) by which Regency will acquire Urstadt Biddle in an all-stock transaction, valued at approximately $1.4 billion, including the assumption of debt and preferred stock. The combined company is expected to have a pro forma equity market capitalization of approximately $11 billion and total enterprise value of approximately $16 billion. Under the terms of the Agreement, Urstadt Biddle’s Class A Common (UBA) and Common (UBP) stockholders will receive 0.347 of a newly-issued REG share for each UBA or UBP share they own, representing...

Continue reading

Legion Capital Announces 2022 Financial Results

Specialized Lender reports second straight year of operating profitability ORLANDO, Fla., May 18, 2023 (GLOBE NEWSWIRE) — Legion Capital (OTC:LGCP), a specialized real estate and business lender providing growth capital to small and medium sized companies and real estate developers, today announced audited financial results for its fiscal year 2022 ended December 31, 2022. Highlights from the 1-K annual report filed are:The Company reported an increased year over year annual profit with a reported operating profit of $1,078,094 compared to a reported operating profit of $279,600 in 2021, an increase of 285%.The Company ended the year with $8,322,114 of cash, compared with $16,898,222 in 2021, a 51% decrease resulting from capital deployment into new loan originations.  Revenue increased to $6,876,274 in 2022 from $3,265,718...

Continue reading

Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA

SHANGHAI, China and CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted priority review to repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). “The CDE’s decision to grant priority review to repotrectinib underscores repotrectinib as a potential next-generation best-in-class treatment for ROS1-positive NSCLC in both TKI-naïve and pretreated patients in China,” said Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development at Zai Lab. “We thank the agency for their commitment and continued support to patients in need, and we look forward to our continued...

Continue reading

CGrowth Capital Inc. Unveils Star Studded Executive Board for Its Sports Division 

NEW YORK, NY, May 18, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – CGrowth Capital Inc. (OTC: CGRA) is a public holding company for alternative and undervalued assets. The company is sector and industry agnostic and is solely focused on investing in growth-oriented opportunities where the company’s capital, expertise, and capabilities can help create significant added value for shareholders. CGrowth Capital Inc. (CGRA) is thrilled to announce an exciting expansion to its executive team with the appointment of a highly experienced board to the company’s sports division. This team, whose members have been updated on the company’s sports division website, brings a wealth of industry experience and a proven track record of delivering exceptional results in the sports industry. The new team’s appointment signals a significant...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.